Hiroyuki Kouji

A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors.

Anthony B. El-Khoueiry, Yan Ning, Dongyun Yang et al. · Journal of Clinical Oncology · 2013 · 118 citations

Medicine, Oncology, Pharmacology +17

Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.

Andrew H. Ko, E. Gabriela Chiorean, Eunice L. Kwak et al. · Journal of Clinical Oncology · 2016 · 69 citations

Medicine, Oncology, Pharmacology +15

E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling

Kazuhiko Yamada, Yusaku Hori, Satoshi Inoue et al. · Cancer Research · 2021 · 61 citations · Full text

Medicine, Oncology, Pharmacology +16

A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.

Robert R. McWilliams, Andrew H. Ko, E. Gabriela Chiorean et al. · Journal of Clinical Oncology · 2015 · 43 citations

Medicine, Oncology, Pharmacology +16

Anti-tumor Activity of the Small Molecule Inhibitor PRI-724 Against β-Catenin-activated Hepatocellular Carcinoma

Ryosuke Gabata, Kenichi Harada, Yuki Mizutani et al. · Anticancer Research · 2020 · 39 citations · Full text

Medicine, Oncology, Pharmacology +14